These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 31383652)
1. Sulfadiazine Sodium Ameliorates the Metabolomic Perturbation in Mice Infected with Toxoplasma gondii. Zhou CX; Gan Y; Elsheikha HM; Chen XQ; Cong H; Liu Q; Zhu XQ Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383652 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil. Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733 [TBL] [Abstract][Full Text] [Related]
3. Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil. Silva LA; Reis-Cunha JL; Bartholomeu DC; Vítor RW PLoS One; 2017; 12(1):e0170689. PubMed ID: 28118394 [TBL] [Abstract][Full Text] [Related]
4. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice. Jost C; Reiter-Owona I; Liesenfeld O Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Romand S; Pudney M; Derouin F Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620 [TBL] [Abstract][Full Text] [Related]
6. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models. Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. Alves CF; Vitor RW Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831 [TBL] [Abstract][Full Text] [Related]
8. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii. Khan AA; Lambert LH; Remington JS; Araujo FG Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177 [TBL] [Abstract][Full Text] [Related]
9. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300 [TBL] [Abstract][Full Text] [Related]
10. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo. Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis. Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693 [TBL] [Abstract][Full Text] [Related]
12. Profiling of the perturbed metabolomic state of mouse spleen during acute and chronic toxoplasmosis. Chen XQ; Zhou CX; Elsheikha HM; He S; Hu GX; Zhu XQ Parasit Vectors; 2017 Jul; 10(1):339. PubMed ID: 28720125 [TBL] [Abstract][Full Text] [Related]
13. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. Martins-Duarte ÉS; de Souza W; Vommaro RC Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807 [TBL] [Abstract][Full Text] [Related]
14. Investigation of urine metabolome of BALB/c mouse infected with an avirulent strain of Toxoplasma gondii. Zhou CX; Li LY; Huang CQ; Guo XD; An XD; Luo FF; Cong W Parasit Vectors; 2022 Jul; 15(1):271. PubMed ID: 35906695 [TBL] [Abstract][Full Text] [Related]
15. In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators. Köksal ZŞ; Yanik K; Bilgin K; Yılmaz EM; Hokelek M Jpn J Infect Dis; 2016; 69(2):113-7. PubMed ID: 26166498 [TBL] [Abstract][Full Text] [Related]
16. Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice. Lindsay DS; Kaur T; Mitchell SM; Goodwin DG; Strobl J; Dubey JP J Parasitol; 2005 Dec; 91(6):1488-90. PubMed ID: 16544426 [TBL] [Abstract][Full Text] [Related]
17. A new iron(III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii. Portes JA; Azeredo NFB; Siqueira PGT; de Souza TG; Fernandes C; Horn A; Candela DRS; de Souza W; DaMatta RA; Seabra SH Parasitol Res; 2018 Sep; 117(9):2795-2805. PubMed ID: 29934691 [TBL] [Abstract][Full Text] [Related]
18. Hepatic Metabolomics Investigation in Acute and Chronic Murine Toxoplasmosis. Chen XQ; Elsheikha HM; Hu RS; Hu GX; Guo SL; Zhou CX; Zhu XQ Front Cell Infect Microbiol; 2018; 8():189. PubMed ID: 29922602 [No Abstract] [Full Text] [Related]
19. Induction of sulfadiazine resistance in vitro in Toxoplasma gondii. Doliwa C; Escotte-Binet S; Aubert D; Velard F; Schmid A; Geers R; Villena I Exp Parasitol; 2013 Feb; 133(2):131-6. PubMed ID: 23206954 [TBL] [Abstract][Full Text] [Related]
20. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. Kovacs JA; Allegra CJ; Chabner BA; Swan JC; Drake J; Lunde M; Parrillo JE; Masur H J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]